MicroRNA-3662 targets ZEB1 and attenuates the invasion of the highly aggressive melanoma cell line A375

References

• Schadendorf D, van Akkooi ACJ, Berking C, et al. Melanoma. Lancet. 2018;392:971–984. doi:10.1016/S0140-6736(18)31559-930238891
   PubMed Web of Science ®Google Scholar
• Carvajal RD, Piperno-Neumann S, Kapiteijn E, et al. Selumetinib in combination with dacarbazine in patients with metastatic uveal melanoma: a phase III, Multicenter, Randomized Trial (SUMIT). J Clin Oncol. 2018;36:1232–1239. doi:10.1200/JCO.2017.74.109029528792
   PubMed Web of Science ®Google Scholar
• Makino E, Gutmann V, Kosnopfel C, et al. Melanoma cells resistant towards MAPK inhibitors exhibit reduced TAp73 expression mediating enhanced sensitivity to platinum-based drugs. Cell Death Dis. 2018;9:930. doi:10.1038/s41419-018-1111-y30206212
   PubMed Web of Science ®Google Scholar
• Zingg D, Debbache J, Peña-Hernández R, et al. EZH2-mediated primary cilium deconstruction drives metastatic melanoma formation. Cancer Cell. 2018;34:69–84, e14. doi:10.1016/j.ccell.2018.06.00130008323
   PubMed Web of Science ®Google Scholar
• Kwiatkowska-Borowczyk E, Czerwińska P, Mackiewicz J, et al. Whole cell melanoma vaccine genetically modified to stem cells like phenotype generates specific immune responses to ALDH1A1 and long-term survival in advanced melanoma patients. Oncoimmunology. 2018;7:e1509821. doi:10.1080/2162402X.2018.149085430377573
   PubMed Web of Science ®Google Scholar
• Cerezo M, Guemiri R, Druillennec S, et al. Translational control of tumor immune escape via the eIF4F-STAT1-PD-L1 axis in melanoma. Nat Med. 2018 [Epub ahead of print]. doi:10.1038/s41591-018-0217-1
   PubMed Web of Science ®Google Scholar
• Marchetti P, Trinh A, Khamari R, Kluza J. Melanoma metabolism contributes to the cellular responses to MAPK/ERK pathway inhibitors. Biochim Biophys Acta Gen Subj. 2018;1862:999–1005. doi:10.1016/j.bbagen.2018.01.01829413908
   PubMed Web of Science ®Google Scholar
• Kuske M, Westphal D, Wehner R, et al. Immunomodulatory effects of BRAF and MEK inhibitors: implications for melanoma therapy. Pharmacol Res. 2018;136:151–159. doi:10.1016/j.phrs.2018.08.01930145328
   PubMed Web of Science ®Google Scholar
• Redmer T. Deciphering mechanisms of brain metastasis in melanoma - the gist of the matter. Mol Cancer. 2018;17:106. doi:10.1186/s12943-018-0854-530053879
   PubMed Web of Science ®Google Scholar
• Alioui A, Dufour J, Leoni V, et al. Retraction Note: liver X receptors constrain tumor development and metastasis dissemination in PTEN-deficient prostate cancer. Nat Commun. 2018;9:2660. doi:10.1038/s41467-018-04653-329973583
   PubMed Web of Science ®Google Scholar
• Ibfelt EH, Steding-Jessen M, Dalton SO, Lundstrøm SL, Osler M, Hölmich LR. Influence of socioeconomic factors and region of residence on cancer stage of malignant melanoma: a Danish nationwide population-based study. Clin Epidemiol. 2018;10:799–807. doi:10.2147/CLEP.S16035730022857
   PubMed Web of Science ®Google Scholar
• Ross KC, Chin KF, Kim D, Marion CD, Yen TJ, Bhattacharjee V. Methotrexate sensitizes drug-resistant metastatic melanoma cells to BRAF V600E inhibitors dabrafenib and encorafenib. Oncotarget. 2018;9:13324–13336. doi:10.18632/oncotarget.2434129568360
   PubMedGoogle Scholar
• Zhang X, Zhang Z, Zhang Q, et al. ZEB1 confers chemotherapeutic resistance to breast cancer by activating ATM. Cell Death Dis. 2018;9:57. doi:10.1038/s41419-018-1111-y29352223
   PubMed Web of Science ®Google Scholar
• Passacantilli I, Panzeri V, Bielli P, et al. Alternative polyadenylation of ZEB1 promotes its translation during genotoxic stress in pancreatic cancer cells. Cell Death Dis. 2017;8:e3168. doi:10.1038/cddis.2017.51829120411
   PubMed Web of Science ®Google Scholar
• Gulei D, Mehterov N, Ling H, Stanta G, Braicu C, Berindan-Neagoe I. The “good-cop bad-cop” TGF-beta role in breast cancer modulated by non-coding RNAs. Biochim Biophys Acta Gen Subj. 2017;1861:1661–1675. doi:10.1016/j.bbagen.2017.04.00728411077
   PubMed Web of Science ®Google Scholar
• Chen L, Mai W, Chen M, et al. Arenobufagin inhibits prostate cancer epithelial-mesenchymal transition and metastasis by down-regulating β-catenin. Pharmacol Res. 2017;123:130–142. doi:10.1016/j.phrs.2017.07.00928712972
   PubMed Web of Science ®Google Scholar
• Nagaraja SS, Nagarajan D. Radiation-induced pulmonary epithelial-mesenchymal transition: a review on targeting molecular pathways and mediators. Curr Drug Targets. 2018;19:1191–1204. doi:10.2174/138945011966618020709223429412104
   PubMed Web of Science ®Google Scholar
• Caramel J, Ligier M, Puisieux A. Pleiotropic roles for ZEB1 in cancer. Cancer Res. 2018;78:30–35. doi:10.1158/0008-5472.CAN-17-247629254997
   PubMed Web of Science ®Google Scholar
• Wu Q, Xiang S, Ma J, et al. Long non-coding RNA CASC15 regulates gastric cancer cell proliferation, migration and epithelial mesenchymal transition by targeting CDKN1A and ZEB1. Mol Oncol. 2018;12:799–813.29489064
   PubMed Web of Science ®Google Scholar
• Viswanathan VS, Ryan MJ, Dhruv HD, et al. Dependency of a therapy-resistant state of cancer cells on a lipid peroxidase pathway. Nature. 2017;547:453–457. doi:10.1038/nature2300728678785
   PubMed Web of Science ®Google Scholar
• Chen Y, Lu X, Montoya-Durango DE, et al. ZEB1 regulates multiple oncogenic components involved in uveal melanoma progression. Sci Rep. 2017;7:45. doi:10.1038/s41598-017-00079-x28246385
   PubMed Web of Science ®Google Scholar
• Matheson JA, Te Marvelde L, Mailer S, et al. Prospective evaluation of prognostic indicators for early recurrence of cutaneous melanoma. Melanoma Res. 2017;27:43–49. doi:10.1097/CMR.000000000000030227753732
   PubMed Web of Science ®Google Scholar
• Ji Q, Xu X, Li L, et al. miR-216a inhibits osteosarcoma cell proliferation, invasion and metastasis by targeting CDK14. Cell Death Dis. 2017;8:e3103. doi:10.1038/cddis.2017.51829022909
   PubMed Web of Science ®Google Scholar
• Liang Y, Xu X, Wang T, et al. The EGFR/miR-338-3p/EYA2 axis controls breast tumor growth and lung metastasis. Cell Death Dis. 2017;8:e2928. doi:10.1038/cddis.2017.51828703807
   PubMed Web of Science ®Google Scholar
• An L, Li DD, Chu HX, et al. Terfenadine combined with epirubicin impedes the chemo-resistant human non-small cell lung cancer both in vitro and in vivo through EMT and Notch reversal. Pharmacol Res. 2017;124:105–115. doi:10.1016/j.phrs.2017.07.02128754458
   PubMed Web of Science ®Google Scholar
• Zhang Y, Li D, Jiang Q, et al. Novel ADAM-17 inhibitor ZLDI-8 enhances the in vitro and in vivo chemotherapeutic effects of sorafenib on hepatocellular carcinoma cells. Cell Death Dis. 2018;9:743.29970890
   PubMed Web of Science ®Google Scholar
• Feng F, Jiang Q, Cao S, et al. Pregnane X receptor mediates sorafenib resistance in advanced hepatocellular carcinoma. Biochim Biophys Acta Gen Subj. 2018;1862:1017–1030. doi:10.1016/j.bbagen.2018.01.01129369785
   PubMed Web of Science ®Google Scholar
• Shao Z, Li Y, Dai W, et al. ETS-1 induces sorafenib-resistance in hepatocellular carcinoma cells via regulating transcription factor activity of PXR. Pharmacol Res. 2018;135:188–200. doi:10.1016/j.phrs.2018.08.00330114438
   PubMed Web of Science ®Google Scholar
• Xie H, Tian S, Yu H, et al. A new apatinib microcrystal formulation enhances the effect of radiofrequency ablation treatment on hepatocellular carcinoma. Onco Targets Ther. 2018;11:3257–3265. doi:10.2147/OTT.S16500029910621
   PubMed Web of Science ®Google Scholar
• Tagliabue E, Gandini S, Bellocco R, et al. MC1R variants as melanoma risk factors independent of at-risk phenotypic characteristics: a pooled analysis from the M-SKIP project. Cancer Manag Res. 2018;10:1143–1154. doi:10.2147/CMAR.S15528329795986
   PubMed Web of Science ®Google Scholar
• Mar VJ, Scolyer RA, Long GV. Computer-assisted diagnosis for skin cancer: have we been outsmarted? Lancet. 2017;389:1962–1964. doi:10.1016/S0140-6736(17)31285-028534744
   PubMed Web of Science ®Google Scholar
• Hammouda MB, Riahi-Chebbi I, Souid S, et al. Macrovipecetin, a C-type lectin from macrovipera lebetina venom, inhibits proliferation migration and invasion of SK-MEL-28 human melanoma cells and enhances their sensitivity to cisplatin. Biochim Biophys Acta Gen Subj. 2018;1862:600–614. doi:10.1016/j.bbagen.2017.11.01929196192
   PubMed Web of Science ®Google Scholar
• Smalley KSM, Forsyth PA. The blood brain barrier and BRAF inhibitors: implications for patients with melanoma brain metastases. Pharmacol Res. 2018;135:265–267. doi:10.1016/j.phrs.2017.11.01329146209
   PubMed Web of Science ®Google Scholar
• Hauschild A, Larkin J, Ribas A, et al. Modeled prognostic subgroups for survival and treatment outcomes in BRAF V600-mutated metastatic melanoma: pooled analysis of 4 randomized clinical trials. JAMA Oncol. 2018;4:1382–1388.30073321
   PubMed Web of Science ®Google Scholar
• McQuade JL, Daniel CR, Hess KR, et al. Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis. Lancet Oncol. 2018;19:310–322. doi:10.1016/S1470-2045(18)30078-029449192
   PubMed Web of Science ®Google Scholar
• van der Hiel B, Haanen JBAG, Stokkel MPM, et al. REPOSIT study group. Vemurafenib plus cobimetinib in unresectable stage IIIc or stage IV melanoma: response monitoring and resistance prediction with positron emission tomography and tumor characteristics (REPOSIT): study protocol of a phase II, open-label, multicenter study. BMC Cancer. 2017;17:649.28915798
   PubMed Web of Science ®Google Scholar
• Chen Z, Zuo X, Zhang Y, et al. MiR-3662 suppresses hepatocellular carcinoma growth through inhibition of HIF-1α-mediated warburg effect. Cell Death Dis. 2018;9:549. doi:10.1038/s41419-018-1111-y29748591
   PubMed Web of Science ®Google Scholar
• Ma S, Deng X, Yang Y, Zhang Q, Zhou T, Liu Z. The lncRNA LINC00675 regulates cell proliferation, migration, and invasion by affecting Wnt/β-catenin signaling in cervical cancer. Biomed Pharmacother. 2018;108:1686–1693. doi:10.1016/j.biopha.2018.10.01130372871
   PubMed Web of Science ®Google Scholar
• Shi K, Qiu X, Zheng W, Yan D, Peng W. MiR-203 regulates keloid fibroblast proliferation, invasion, and extracellular matrix expression by targeting EGR1 and FGF2. Biomed Pharmacother. 2018;108:1282–1288. doi:10.1016/j.biopha.2018.09.15230372829
   PubMed Web of Science ®Google Scholar
• Lu Y, Lian S, Ye Y, et al. S-nitrosocaptopril prevents cancer metastasis in vivo by creating the hostile bloodstream microenvironment against circulating tumor cells. Pharmacol Res. 2018 pii: S1043-6618(18)30400-6 [Epub ahead of print]. doi: 10.1016/j.phrs.2018.10.020
   Web of Science ®Google Scholar
• Kurata T, Fushida S, Kinoshita J, et al. Low-dose eribulin mesylate exerts antitumor effects in gastric cancer by inhibiting fibrosis via the suppression of epithelial-mesenchymal transition and acts synergistically with 5-fluorouracil. Cancer Manag Res. 2018;10:2729–2742. doi:10.2147/CMAR.S16784630147370
   PubMed Web of Science ®Google Scholar
• Cao G, Chen D, Liu G, Pan Y, Liu Q. CPEB4 promotes growth and metastasis of gastric cancer cells via ZEB1-mediated epithelial- mesenchymal transition. Onco Targets Ther. 2018;11:6153–6165. doi:10.2147/OTT.S17542830288051
   PubMed Web of Science ®Google Scholar
• Kyriakopoulou K, Kefali E, Piperigkou Z, Bassiony H, Karamanos NK. Advances in targeting epidermal growth factor receptor signaling pathway in mammary cancer. Cell Signal. 2018;51:99–109. doi:10.1016/j.cellsig.2018.07.01030071291
   PubMed Web of Science ®Google Scholar
• Zhang C, Zhang Y, Zhu H, Hu J, Xie Z. MiR-34a/miR-93 target c-Ski to modulate the proliferaton of rat cardiac fibroblasts and extracellular matrix deposition in vivo and in vitro. Cell Signal. 2018;46:145–153. doi:10.1016/j.cellsig.2018.03.00529551367
   PubMed Web of Science ®Google Scholar
• Li X, Li Z, Li X, Liu B, Liu Z. Mechanisms of Tanshinone II a inhibits malignant melanoma development through blocking autophagy signal transduction in A375 cell. BMC Cancer. 2017;17(1):357. doi:10.1186/s12885-017-3329-y28532456
   PubMed Web of Science ®Google Scholar
• Richard G, Dalle S, Monet MA, et al. ZEB1-mediated melanoma cell plasticity enhances resistance to MAPK inhibitors. EMBO Mol Med. 2016;8(10):1143–1161. doi:10.15252/emmm.20150597127596438
   PubMed Web of Science ®Google Scholar
• Pal HC, Diamond AC, Strickland LR, et al. Fisetin, a dietary flavonoid, augments the anti-invasive and anti-metastatic potential of sorafenib in melanoma. Oncotarget. 2016;7(2):1227–1241. doi:10.18632/oncotarget.623726517521
   PubMedGoogle Scholar
• Caramel J, Papadogeorgakis E, Hill L, et al. A switch in the expression of embryonic EMT-inducers drives the development of malignant melanoma. Cancer Cell. 2013;24(4):466–480. doi:10.1016/j.ccr.2013.08.01824075834
   PubMed Web of Science ®Google Scholar
• Shahid S, Kim G, Johnson NR, et al. MicroRNAs from the parasitic plant cuscuta campestris target host messenger RNAs. Nature. 2018;553(7686):82–85. doi:10.1038/nature2502729300014
   PubMed Web of Science ®Google Scholar
• Li L, Kang L, Zhao W, et al. miR-30a-5p suppresses breast tumor growth and metastasis through inhibition of LDHA-mediated warburg effect. Cancer Lett. 2017;400:89–98. doi:10.1016/j.canlet.2017.04.03428461244
   PubMed Web of Science ®Google Scholar
• Li J, Zhao J, Wang H, et al. MicroRNA-140-3p enhances the sensitivity of hepatocellular carcinoma cells to sorafenib by targeting pregnenolone X receptor. Onco Targets Ther. 2018;11:5885–5894. doi:10.2147/OTT.S17950930271172
   PubMed Web of Science ®Google Scholar
• Meng D, Lei M, Han Y, et al. MicroRNA −645 targets urokinase plasminogen activator and decreases the invasive growth of MDA-MB-231 triple-negative breast cancer cells. Onco Targets Ther. 2018;11:7733–7743. doi:10.2147/OTT.S18722130464522
   PubMed Web of Science ®Google Scholar